Abstract
In late 2000 coronary vascular brachytherapy (VBT) was approved for routine clinical use in the United States. In January 2001 the Novoste BetaCath system was initiated into routine management of patients with in-stent restenosis at Emory University. In March 2002 the Guidant Galileo system was acquired and made available for this same group of patients. We describe below a real-world experience with VBT at Emory.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Paper Title
Journal
Date
